Esomeprazole

Generic Name
Esomeprazole
Brand Names
Nexium, Vimovo, Nexium Control
Drug Type
Small Molecule
Chemical Formula
C17H19N3O3S
CAS Number
119141-88-7
Unique Ingredient Identifier
N3PA6559FT
Background

Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of H. pylori infections along with other antibiotics including Amoxicillin, Clarithromycin, and Metronidazole, for example. Its efficacy is considered similar to other medications within the PPI class including Omeprazole, Pantoprazole, Lansoprazole, Dexlansoprazole, and Rabeprazole. Esomeprazole is the s-isomer of Omeprazole, which is a racemate of the S- and R-enantiomer. Esomeprazole has been shown to inhibit acid secretion to a similar extent as Omeprazole, without any significant differences between the two compounds in vitro.

Esomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at the secretory surface of gastric parietal cells. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. As the binding of esomeprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, esomeprazole's duration of antisecretory effect persists longer than 24 hours.

PPIs such as esomeprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes.

Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as esomeprazole has been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal C. difficile), reduced absorption of micronutrients such as iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.

Rapid discontinuation of PPIs such as esomeprazole may cause a rebound effect and a short term increase in hypersecretion. Esomeprazole doses should be slowly lowered, or tapered, before discontinuing to prevent this rebound effect.

Indication

Esomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome.

Associated Conditions
Duodenal Ulcer, Erosive Esophagitis, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Stress Ulcers, Upper Gastrointestinal Hemorrhage, Zollinger-Ellison Syndrome, Acute benign gastric ulcers, Develop NSAID-induced gastric ulcers, Maintenance of healing Erosive esophagitis, Postendoscopy Bleeding
Associated Therapies
-

High Dose of Dual Therapy Plus Bismuth for Helicobacter Pylori Treatment

First Posted Date
2018-01-23
Last Posted Date
2018-11-05
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
160
Registration Number
NCT03405584
Locations
šŸ‡ØšŸ‡³

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy

First Posted Date
2017-12-26
Last Posted Date
2019-01-30
Lead Sponsor
Chang Gung Memorial Hospital
Target Recruit Count
240
Registration Number
NCT03383003
Locations
šŸ‡ØšŸ‡³

Wei-Chen Tai, Kaohsiung, Taiwan

Pharmacokinetics and Safety Studies of Esomeprazole Use in Schizophrenia Patients

Phase 4
Completed
Conditions
Interventions
First Posted Date
2017-11-07
Last Posted Date
2018-03-29
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
25
Registration Number
NCT03333603
Locations
šŸ‡ØšŸ‡³

National Taiwan University Hospital Yunlin Branch, Taipei, Taiwan

šŸ‡ØšŸ‡³

National Taiwan University Hospital, Taipei, Taiwan

The Effect of Broccoli Sprout Extract and Probiotics for Eradication of Helicobacter Pylori

First Posted Date
2017-07-18
Last Posted Date
2019-06-04
Lead Sponsor
Kyunghee University Medical Center
Target Recruit Count
360
Registration Number
NCT03220542
Locations
šŸ‡°šŸ‡·

Kyung Hee University Hospital, Seoul, Korea, Republic of

A Study to Compare PK, PD and Safety of CKD-381 in Healthy Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2017-07-07
Last Posted Date
2017-11-21
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
41
Registration Number
NCT03211143
Locations
šŸ‡°šŸ‡·

Severance Hospital, Seoul, Korea, Republic of

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)

First Posted Date
2017-06-12
Last Posted Date
2020-09-03
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
Target Recruit Count
211
Registration Number
NCT03184324
Locations
šŸ‡°šŸ‡·

Hanyang University Medical Center, Sungdong-gu, Seoul, Korea, Republic of

Effect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study

First Posted Date
2017-05-05
Last Posted Date
2017-05-05
Lead Sponsor
Chinese University of Hong Kong
Target Recruit Count
96
Registration Number
NCT03142620
Locations
šŸ‡­šŸ‡°

Prince of Wales Hospital, Hong Kong, Hong Kong

A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.

Phase 1
Completed
Conditions
Interventions
First Posted Date
2017-05-02
Last Posted Date
2017-10-31
Lead Sponsor
Pfizer
Target Recruit Count
18
Registration Number
NCT03137134
Locations
šŸ‡ŗšŸ‡ø

Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Drug-drug Interaction Between Aceclofenac 200 mg and Esomeprazole 20 mg in Healthy Male Volunteers

First Posted Date
2017-04-25
Last Posted Date
2017-04-25
Lead Sponsor
Dong Wha Pharmaceutical Co. Ltd.
Target Recruit Count
30
Registration Number
NCT03127046
Locations
šŸ‡°šŸ‡·

Chonbuk National University Hospital., Jeonju-si, Jeollabuk-do, Korea, Republic of

10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection

Phase 4
Completed
Conditions
Interventions
First Posted Date
2016-11-09
Last Posted Date
2018-03-29
Lead Sponsor
Elpen Pharmaceutical Co. Inc.
Target Recruit Count
364
Registration Number
NCT02959255
Locations
šŸ‡¬šŸ‡·

Army Hospital, Athens, Greece

Ā© Copyright 2024. All Rights Reserved by MedPath